97 related articles for article (PubMed ID: 28736321)
1. An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
Tammela TL; Häggman M; Ladjevardi S; Taari K; Isotalo T; Lennernäs H; Weis J; von Below C; Wassberg C; Lennernäs B; Tolf A; Axén N; Gölander CG; Ahlström H
J Urol; 2017 Dec; 198(6):1333-1339. PubMed ID: 28736321
[TBL] [Abstract][Full Text] [Related]
2. Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients.
Klotz L; Grudén S; Axén N; Gauffin C; Wassberg C; Bjartell A; Giddens J; Incze P; Jansz K; Jievaltas M; Rendon R; Richard PO; Ulys A; Tammela TL
Eur Urol Focus; 2022 Jan; 8(1):112-120. PubMed ID: 33583762
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model.
Sjögren E; Tammela TL; Lennernäs B; Taari K; Isotalo T; Malmsten LÅ; Axén N; Lennernäs H
Mol Pharm; 2014 Sep; 11(9):3097-111. PubMed ID: 25055161
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
5. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
6. Local injection of a sustained-release antiandrogen formulation into a target prostatic site: an experimental study.
Goya N; Gotanda K; Sasaki T; Okada M; Tomizawa Y; Toma H
BJU Int; 2007 Jan; 99(1):202-6. PubMed ID: 17092292
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Kawabata R; Oie S; Oka T; Takahashi M; Kanayama H; Itoh K
Int J Oncol; 2011 Mar; 38(3):665-76. PubMed ID: 21243325
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyflutamide may not always be a pure antiandrogen.
Yeh S; Miyamoto H; Chang C
Lancet; 1997 Mar; 349(9055):852-3. PubMed ID: 9121269
[No Abstract] [Full Text] [Related]
9. [Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients].
Harano M; Kano M; Hida T; Fujisawa Y; Kano M
Gan To Kagaku Ryoho; 2004 Mar; 31(3):377-80. PubMed ID: 15045944
[TBL] [Abstract][Full Text] [Related]
10. [Antiandrogen suppression syndrome in patients with hormone-resistant cancer of the prostate].
Morote Robles J; Lorente Garín JA; Encabo G
Actas Urol Esp; 1998 Sep; 22(8):661-5. PubMed ID: 9835085
[TBL] [Abstract][Full Text] [Related]
11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
12. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
13. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
[TBL] [Abstract][Full Text] [Related]
14. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.
Schulz M; Schmoldt A; Donn F; Becker H
Eur J Clin Pharmacol; 1988; 34(6):633-6. PubMed ID: 3169114
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
17. Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.
Kamiya N; Suzuki H; Nishimura K; Fujii M; Okegawa T; Matsuda T; Morita T; Takihana Y; Ozono S; Namiki M; Matsubara A; Ichikawa T; Miki T
Jpn J Clin Oncol; 2014 Mar; 44(3):263-9. PubMed ID: 24516203
[TBL] [Abstract][Full Text] [Related]
18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
19. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
Paul R; Breul J
Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
